GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » Long-Term Debt

GENinCode (LSE:GENI) Long-Term Debt : £0.00 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is GENinCode Long-Term Debt?

GENinCode's Long-Term Debt for the quarter that ended in Jun. 2024 was £0.00 Mil.

GENinCode Long-Term Debt Historical Data

The historical data trend for GENinCode's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GENinCode Long-Term Debt Chart

GENinCode Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Debt
- - - - -

GENinCode Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GENinCode  (LSE:GENI) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

GENinCode Long-Term Debt Related Terms

Thank you for viewing the detailed overview of GENinCode's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

GENinCode Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » Long-Term Debt
Comparable Companies
LSE:GDR LSE:VRCI LSE:PRM LSE:ABDX LSE:LLAI LSE:AGL TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD WAT NTRA LH DGX XPAR:BIM ICLR
Traded in Other Exchanges
N/A
Address
Oxford Science Park, John Eccles House, Robert Robertson Avenue, Oxford, GBR, OX4 4GP
Website
https://www.genincode.com
GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment the sale of kits and the provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain, and the United Kingdom.